Cash-strapped Sirnaomics seeks lifeline in cosmetic treatments
The biotech is suing its former CEO over an ill-fated $20 million investment as it pursues a short-term pivot from skin cancer drugs to body-contouring therapies Key Takeaways: After the…
Alphamab seals $2.2 billion licensing deal with AI biotech
The Chinese drug firm has chosen to partner with an AI specialist rather than Big Pharma on a dual-target cancer therapy, netting an upfront payment of $125 million Key Takeaways:…
PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
The developer of anti-inflammatory treatments will need to persuade investors to look past its balance sheet problems and its narrow pipeline of products Key Takeaways: The company is making a…
Legend Bio CEO resigns, shares tumble
Drugmaker Legend Biotech Corp. (LEGN.US) said on Monday that Huang Ying resigned as the company’s CEO and member of its board effective July 24, without giving any reason for his departure.…
Insilico revenue soars above $100 million on AI drug partnerships
The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals Key Takeaways: Insilico expects to power into…
Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
Alebund soars in Hong Kong debut on kidney treatment hopes
The drug developer stood out from the IPO crowd of unprofitable biotechs due to its existing revenue stream and a focus on novel remedies for renal disease Key Takeaways: Alebund…
Recent Articles
RELATED ARTICLES
-
AI in China’s medical aesthetics sector: From non-core services to clinical device integration
- Extransfer seeks Hong Kong IPO as accounting losses hide a cash cow
- PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
- Luzhu Biotech braces for make-or-break launch of shingles shot
- Eye drug maker VivaVision feels the strain in IPO funding dash
- Cash-challenged Tenways cycles toward IPO
-
Plummeting cash flow and a stake-trimming top shareholder: What’s up at Zhejiang Shibao?
1057.HK002703.SHE
